Navigation Links
Amedica(R) Signs Joint Venture Agreement With Orthopaedic Synergy(R)
Date:2/22/2010

SALT LAKE CITY, Feb. 22 /PRNewswire/ -- Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.

Amedica is a full-line spinal implant company that owns and markets silicon nitride ceramic technologies that are now being utilized in spinal implant applications; however, the unique SiN materials have disruptive characteristics for hip and knee implant applications, as well.  The material is fracture resistant; its bearing/articulating surfaces do not produce wear debris that is linked to osteolysis-related, re-operations.  Additionally, the implants are BioActive™ with a hydrophilic surface and a conductive cancellous structure to enhance bone in-growth and attachment.

The Joint Venture Development Agreement will allow the development, regulatory approval and distribution of SiN articulating hip and knee implants in the U.S. and abroad.  This agreement further secures both companies' competitive positions in the largest segment of orthopaedic care.

Orthopaedic Synergy is a global reconstructive hip and knee implant and instrument concern that designs, manufactures and distributes its products.  Its corporate headquarters is located in East Taunton, Mass., and its design, development and manufacturing center is based in Christchurch, New Zealand. OSI is known for leading-edge innovation, cost-effective, outcome-focused implant systems and deep orthopaedic executive management experience.  

"Amedica's SiN technology is ideally suited for the innovative modular hip and knee replacement products developed and marketed by our company, and we view this Joint Venture Development Agreement as a significant step forward in solving the issue of wear in reconstructive orthopaedic products," says Nik Nikolaev, Chairman and Chief Executive Officer of Orthopaedic Synergy, Inc.

"Finding the appropriate material to use as a bearing surface in Total Joint Arthroplasty has been an elusive goal, especially for Total Hip Replacement. We have been investigating alternate materials for some time, and we are convinced that Amedica's  SiN technology is the answer. We are proud that they chose OSI to be their partner," says George Cipolletti, President of OMNIlife Science.  

"We are pleased that this agreement is now in place.  SiN is a disruptive human implant material that has application in spine, reconstructive surgery and other orthopaedic implant indications.  We are honored to be in this relationship with Orthopaedic Synergy – it is truly an alliance that, in time, can clearly enhance patient outcomes," says Ben Shappley, Chief Executive Officer, President and Director of Amedica.

About Orthopaedic Synergy:

Orthopaedic Synergy, Inc. is a global reconstructive orthopaedic concern that functions as a holding company for OMNIlife Science, Inc. and Enztec, Ltd.  The Company designs, develops and distributes FDA cleared and CE approved reconstructive orthopaedic implants that represent leading edge technologies.

About Amedica:

Amedica Corporation is ISO 13485 certified and its products are FDA cleared and CE approved.  Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market.  It has brought to market various spinal implant products, while products under development include reconstructive hip and knee implants that represent a new standard of care in total joint implants based on superior performance, safety and efficacy.

SOURCE Amedica Corporation

Back to top

RELATED LINKS
http://www.amedicacorp.com

'/>"/>

SOURCE Amedica Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
2. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
3. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
4. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
5. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
6. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
11. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... Oregon and PUNE, India , January 18, 2017 ... Research, titled, "Polyphenol Market by Product Type and by Application: Global Opportunity Analysis ... $757 million in 2015, and is expected to reach $1,127 million by 2022, ... the market in 2015, with two-fifths share, in terms of revenue. ... ...
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact on ... Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... in order to thrive this year? , The passage of the act means devicemakers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today that Dan Grover ... and marketing strategies. Grover comes with a total of 15 years experience in consumer ... as Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... age-related lines and wrinkles. Few people know that popular cosmetic fillers ... Richard Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
Breaking Medicine News(10 mins):